1

Biocon

#2785

Rank

$4.93B

Marketcap

IN India

Country

Biocon
Leadership team

Ms. Kiran Mazumdar-Shaw B.Sc (Hons), B.Sc. (Founder & Exec. Chairperson)

Mr. Siddharth Mittal BCom, CA, CPA (MD, CEO & Director)

Mr. Indranil Sen (Chief Financial Officer)

Products/ Services
Biopharma, Biotechnology, Health Care, Medical
Number of Employees
1,000 - 20,000
Headquarters
Bangalore, Karnataka, India
Established
1978
Net Income
100M - 500M
Revenue
Above - 1B
Traded as
BIOCON.NS
Social Media
Overview
Location
Summary
Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, It is involved in the integrated discovery, development, and manufacturing services for small and large molecules. The company serves customers in approximately 120 countries. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.
History

Biocon was founded in 1978 with Rs.10,000 as the initial capital.

1979 - Becomes the first Indian company to manufacture and export enzymes to the US and Europe.

1989 - Unilever acquires Biocon Biochemicals Ltd. in Ireland and merges it with its subsidiary, Quest International; Biocon receives US funding for proprietary technologies.

1994 - Establishes Syngene International Pvt. Ltd. as a Custom Research Company .

1998 - Unilever agrees to sell its shareholding in Biocon to the Indian promoters. Biocon becomes an independent entity.

2001 - Becomes the first Indian company to be approved by USFDA for the manufacture of lovastatin; PlaFractor is granted a US 2001 and worldwide patent.

2003 - Biocon becomes the first company worldwide to develop human insulin on a Pichia expression system.

2006 - BIOMAb EGFR, first indigenously developed humanised monoclonal antibody for head-and-neck cancer is launched and Dr. APJ Abdul Kalam inaugurates India's Largest Biotech-Hub "Biocon Park".

* 2008 - Biocon acquires a 70% stake in German pharmaceutical company, AxiCorp GmbH.

2009 - Syngene-Bristol Myers Squibb research facility is established in Bengaluru.

2009 - Mylan announces strategic collaboration with Biocon to Enter the Global Generic Biologics Market.

2010 - Biocon expands to Malaysia, biopharmaceutical manufacturing and R&D facility established in Iskandar Malaysia, Johor.

2011 - Biocon launches INSUPen®, a convenient and affordable reusable insulin delivery device.

2012 - Abbott announces collaboration with Syngene to Open First Nutrition R&D Center in India.

2013 - Biocon launches biologic drug ALZUMAb to treat psoriasis.

2014 - Biocon launches world's first biosimilar drug CANMAb to treat breast cancer.

2015 - Biocon launches hepatitis-C drug in India under brand name CIMIVIR-L.

2016 - Becomes the first Indian company to launch a biosimilar Insulin Glargine pen in Japan.

2016 - Syngene sets up Amgen R&D center in Bangalore.

2017 - Biocon's Insugen is the first locally manufactured biosimilar product to be approved for sale by the Malaysian drug regulator.

2017 - USFDA approves Mylan-Biocon's biosimilar for cancer drug Herceptin.

2018 - Biocon, Mylan get European Commission approval to market biosimilar insulin glargine.

2021 - Biocon Biologics and Serum Institute of India formed a joint agreement to commercialise vaccines, biological drugs, and antibody therapies together. Another aspect of the deal involves Bicocon selling 15% of its biologics subsidiary to Serum Institute of India, in return for Biocon gaining access to 100 million annual doses of vaccines for a 15-year period.

2022 - Biocon Biologics buys the biosimilar assets of Viatris, for $3.34 billion.

Mission
Biocon's mission is to deliver breakthrough biopharmaceutical solutions to address unmet medical needs of patients & to make access to life saving medicines, innovative & affordable.
Vision
Biocon’s vision is to be an integrated, innovation-driven biopharmaceutical enterprise striving to enhance affordability & accessibility of complex therapies to patients globally.
Key Team

Ms. Seema Shah Ahuja BA, MBA (Global Head of Communications & Corp. Brand)

S. Vijaya Kumar (Head of Operations)

Mr. Saurabh Paliwal (Head of Investor Relations)

Mr. Amitava Saha (Chief HR Officer)

Mr. Mayank Verma (Company Sec. & Compliance Officer)

Mr. Sandeep Rao M.Sc., PGDM (Sr. VP)

Dr. A. V. Sriram (Head of Quality)

Recognition and Awards
Biocon has been recognised with several awards, including the United Nations Environment Programme – Global 500 award, the Japan’s Deming Prize for Quality, The Emerging Market Leader of India award from the World Economic Forum, Nasscom IT User award, ET Now BPO Company of the Year in Pharmaceuticals, the ET Now Award for 'Corporate Citizen of the Year', and the Red Herring 100 Asia Award.
References
Biocon
Leadership team

Ms. Kiran Mazumdar-Shaw B.Sc (Hons), B.Sc. (Founder & Exec. Chairperson)

Mr. Siddharth Mittal BCom, CA, CPA (MD, CEO & Director)

Mr. Indranil Sen (Chief Financial Officer)

Products/ Services
Biopharma, Biotechnology, Health Care, Medical
Number of Employees
1,000 - 20,000
Headquarters
Bangalore, Karnataka, India
Established
1978
Net Income
100M - 500M
Revenue
Above - 1B
Traded as
BIOCON.NS
Social Media